Summary
Since 1978, over 50 clinically useful antitumor drugs or new candidate antitumor agents have been evaluated in vivo against cisplatin-resistant P388 leukemia (P388/DDPt) in our laboratories. Analysis of this data base has yielded insights into the cross-resistance, collateral sensitivity, and mechanisms of resistance of P388/DDPt. P388/DDPt was cross-resistant or marginally crossresistant to eight agents [carmethizole·HCl, rhizoxin, dibromodulcitol, spirohydantoin mustard, hepsulfam, arabinosyl-5-azacytosine (ara-AC), tiazofurin, and deoxyspergualin]. Of these eight agents, the latter six have entered various phases of clinical trials. For these trials, it may be important to exclude or to monitor with extra care patients who have previously been treated with cisplatin. P388/DDPt was collaterally sensitive to six agents [fludarabine phosphate (2-F-ara-AMP), amsacrine (AMSA), mitoxantrone, etoposide (VP-16), batracylin, and flavone acetic acid] and, possibly, to two others (merbarone and echinomycin). These observations of collateral sensitivity suggest that a combination of cisplatin plus any one of these drugs might exhibit therapeutic synergism. Therapeutic synergism has been observed in animal models for combinations of cisplatin plus VP-16, AMSA, or mitoxantrone. The observation of collateral sensitivity for P388/DDPt to four agents (AMSA, mitoxantrone, merbarone, and VP-16) that have been reported to interact with DNA topoisomerase II suggests the possible involvement of the latter in cisplatin resistance. Both the increased sensitivity of P388/DDPt to these agents and a portion of its resistance to cisplatin could be the result of an increase in DNA topoisomerase II activity.
Similar content being viewed by others
Abbreviations
- AMSA:
-
amsacrine
- ara-AC:
-
arabinosyl-5-azacytosine
- DTP:
-
Developmental Therapeutics Program
- DCT:
-
Division of Cancer Treatment
- 2-F-ara-AMP:
-
fludarabine phosphate
- GSH:
-
glutathione
- ILS:
-
increase in life span
- LD10 :
-
dose producing lethality in 10% of the test group
- NCI:
-
National Cancer Institute
- P388/DDPt:
-
cisplatin-resistant P388 leukemia
- P388/0:
-
cisplatin-sensitive P388 leukemia
- VP-16:
-
etoposide
References
Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35
Cummings J, Smyth JF (1989) Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours. Cancer Chemother Pharmacol 24: 269
Drake FH, Hofmann GA, Mong S-M, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578
Dykes DJ, Waud WR, Harrison SD Jr, Laster WR Jr, Griswold DP Jr, Shealy YF, Montgomery JA (1989) Antitumor activity of 2-chloroethyl (methylsulfonyl) methanesulfonate (Clomesone, NSC 338947) against selected tumor systems in mice. Cancer Res 49: 1182
Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R (1986) Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70: 1105
Grem JL, Shoemaker DD, Hoth DF, King SA, Plowman J, Zaharko D, Grieshaber CK, Harrison SD Jr, Cradock JC, Leyland-Jones B (1987) Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. Invest New Drugs 5: 315
Harrison SD Jr, O'Dwyer PJ, Trader MW (1986) Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice. Cancer Res 46: 3396
Harrison SD Jr, Brockman RW, Trader MW, Laster WR Jr, Griswold DP Jr (1987) Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo. Invest New Drugs 5: 345
Harrison SD Jr, Plowman J, Dykes DJ, Waud WR, Griswold DP Jr (1990) Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo. Cancer Chemother Pharmacol 25: 425
Ho AD, Seither E, Ma DDF, Prentice G (1987) Mitoxantrone-induced toxicity and DNA strand breaks in leukemic cells. Br J Haematol 65: 51
Jong S de, Timmer-Bosscha H, Vries EGE de, Mulder NH (1990) Increased topoisomerase II activity in a cisplatin resistant cell line. Proc Am Assoc Cancer Res 31: 337
Kraker AJ, Moore CW (1988) Elevated DNA polymerase beta activity in acis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line. Cancer Lett 38: 307
Lloyd HH (1977) Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM (eds) Growth kinetics and biochemical regulation of normal and malignant cells. Williams & Wilkins, Baltimore, p 455
Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance tocis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48: 5713
Nelson EM, Tewey KM, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino) methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361
Plowman J, Paull KD, Atassi G, Harrison SD Jr, Dykes DJ, Kabbe HJ, Narayanan VL, Yoder OC (1988) Preclinical antitumor activity of batracylin (NSC 320 846). Invest New Drugs 6: 147
Ross W, Rowe T, Glisson B, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857
Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J (1989) Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9: 1301
Scanlon KJ, Kashani-Sabet M, Sowers LC (1989) Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1: 269
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther [A] 1: 411
Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr (1979)cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459
Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905 (see correction, Cancer Treat Rep 68: 453)
Sriram R, Ali-Osman F, Livingston R, Ellis G, Needle MN, Stein D (1990) Modulation of topoisomerase (Topo) II on the kinetics of formation and repair of cis-platinum (cis-DDP) induced DNA-interstrand crosslinks (DNA-ISC) in human tumor cells sensitive and resistant to cis-DDP. Proc Am Assoc Cancer Res 31: 335
Tan KB, Mattern MR, Boyce RA, Schein PS (1987) Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells. Proc Natl Acad Sci USA 84: 7668
Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E III (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457
Tsai C-M, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS (1989) Lack of in vitro synergy between etoposide andcis-diamminedichloroplatinum(II). Cancer Res 49: 2390
Tseng W-C, Derse D, Cheng Y-C, brockman RW, Bennett LL Jr (1982) In vitro biological activity of 9-β-d-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21: 474
Waring MJ, Wakelin LPG (1974) Echinomycin: a bifunctional intercalating antibiotic. Nature 252: 653
Waud WR (1987) Differential uptake ofcis-diamminedichloroplatinum(II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res 47: 6549
Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr (1990) Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waud, W.R., Harrison, S.D., Gilbert, K.S. et al. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother. Pharmacol. 27, 456–463 (1991). https://doi.org/10.1007/BF00685160
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685160